Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSR | P00390 | 2/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.44 |
| ▸ | GRM8 | O00222 | 1/20 | 0.44 |
| ▸ | GRM6 | O15303 | 1/20 | 0.44 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.44 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.44 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.44 |
| ▸ | GRM5 | P41594 | 1/20 | 0.44 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.44 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.44 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.44 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.44 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.44 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.44 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.44 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.44 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.44 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.44 |
| ▸ | GRIK3 | Q13003 | 1/20 | 0.44 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29891046 | 1.00 | GSR (0.46) | GSRCYP1A2GRM8GRM6GRIN2D | |
| SCHEMBL12463782 | 1.00 | GSR (0.46) | GSRCYP1A2GRM8GRM6GRIN2D | |
| SCHEMBL825904 | 0.95 | GSR (0.48) | GSRCYP1A2GRM8GRM6GRIN2D | |
| SCHEMBL29579375 | 0.93 | GSR (0.47) | GSRCYP1A2GRM8GRM6GRIN2D | |
| SCHEMBL3858559 | 0.93 | GSR (0.47) | GSRCYP1A2GRM8GRM6GRIN2D | |
| SCHEMBL5968392 | 0.93 | GSR (0.47) | GSRCYP1A2GRM8GRM6GRIN2D | |
| SCHEMBL4758907 | 0.93 | GSR (0.47) | GSRCYP1A2GRM8GRM6GRIN2D | |
| SCHEMBL172526 | 0.89 | SLC1A1 (0.52) | GSRCYP1A2GRM8GRM6GRIN2D | |
| SCHEMBL1411236 | 0.89 | SLC1A1 (0.52) | GSRCYP1A2GRM8GRM6GRIN2D | |
| SCHEMBL130831 | 0.89 | SLC1A1 (0.52) | GSRCYP1A2GRM8GRM6GRIN2D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116178293-B | Myelin specific magnetic resonance contrast agent, preparation method and application thereof | 滨州医学院附属医院 | 2025-05-09 | — | — | CN | disclosed |
| WO-2023143608-A1 | COMPOSITION, METHOD FOR PREPARING SAME, AND USE THEREOF | 上海复东生物医药有限责任公司 | 2023-08-03 | — | — | WO | disclosed |
| CN-116178293-A | Myelin specific magnetic resonance contrast agent, preparation method and application thereof | 滨州医学院附属医院 | 2023-05-30 | — | — | CN | disclosed |
| EP-3305900-A1 | ENZYMATIC ENCODING METHODS FOR EFFICIENT SYNTHESIS OF LARGE LIBRARIES | Nuevolution A/S (DK) | 2018-04-11 | — | — | EP | disclosed |
| CN-1950343-B | Amine-based basic compound and use thereof | KUREHA CORP | 2013-06-19 | — | — | CN | disclosed |
| US-8263608-B2 | Melanocortin receptor-specific spiro-piperidine compounds | PALATIN TECHNOLOGIES, INC. (US) | 2012-09-11 | — | — | US | disclosed |
| US-20110178080-A1 | Melanocortin Receptor-Specific Spiro-Piperidine Compounds | PALATIN TECHNOLOGIES, INC. (US) | 2011-07-21 | — | — | US | disclosed |
| WO-2010037081-A1 | MELANOCORTIN RECEPTOR-SPECIFIC SPIRO-PIPERIDINE COMPOUNDS | PALATIN TECHNOLOGIES, INC. (US) | 2010-04-01 | — | — | WO | disclosed |
| CN-101605756-A | The water-soluble prodrug of florfenicol and analogue thereof | SCHERING PLOUGH LTD (CH) | 2009-12-16 | — | — | CN | disclosed |
| CN-101094840-A | Quinazoline derivatives for inhibiting the growth of cancer cells and methods for preparing the same | HANMI PHARM IND CO LTD (KR) | 2007-12-26 | — | — | CN | disclosed |
| CN-1950343-A | Amine-based basic compound and use thereof | KUREHA CORP (JP) | 2007-04-18 | — | — | CN | disclosed |
| EP-1590334-A1 | 2,4-DIAMINOPYRIMIDINE DERIVATIVES USEFUL AS INHIBITORS OF PKC-THETA | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 2005-11-02 | — | — | EP | disclosed |
| WO-2004067516-A1 | 2,4-DIAMINOPYRIMIDINE DERIVATIVES USEFUL AS INHIBITORS OF PKC-THETA | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2004-08-12 | — | — | WO | disclosed |
| WO-1995023811-A1 | NOVEL CARBOCYCLIC COMPOUNDS WHICH INHIBIT PLATELET AGGREGATION BY INTERACTION WITH THE GPIIB/IIIA RECEPTOR COMPLEX | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1995-09-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110178080-A1 | Melanocortin Receptor-Specific Spiro-Piperidine Compounds | MC1R, MC5R, MC3R | GSR 3006/4885CYP1A2 2616/4885GRM8 383/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.